Lifesciences@Work : We help scientists build their business

Don’t forget to register for the LS@W Expert Class about HTA & Reimbursement

Great Friday Afternoon planned for 15 February 2019 about Health Technology Assessment (HTA) and Reimbursement.

Our upcoming Expert Class is organised in collaboration with IXA Innovation Exchange Amsterdam, Amsterdam UMC- University of Amsterdam, Agendia, Sanofi and CbusineZ. Experts from these renowned organisations are willing to invest time to present their views to you. In addition, more experienced professionals will participate to talk to you about HTA, entrepreneurship, legal affairs, and time-to-market.

We hope to welcome you (again) at the LS@W Expert Class. The programme starts at 12:00 hrs, lunch and ‘borrel’ are included. Download the programme >

Participation is again free for startups. Be there and realize how valuable these connections can be! Register here >

Contributing organisations


Corianne de Borgie, Amsterdam UMC – University of Amsterdam, Head Clinical Methodology of clinical research

Jeroen Nugteren, CbusineZ, Business Manager

Sari Neijenhuis, Agendia, Medical Director EU

Lars Wormhoudt, Sanofi, Head market access NL

Michelle Meeks, IXA Innovation Exchange Amsterdam (IXA), Business Development Manager


Health Technology: any aspect of healthcare and includes Diagnostic, Medical Devices, Drugs, Therapies, Medical Procedures, Prevention programmes etc.

Health Technology Assessment (HTA): policy research that examines the short and long-term consequences of using a healthcare technology. It is a multidisciplinary process that summarizes information about the medical, social, economic and ethical issues related to the use of a health technology in a systematic, transparent, unbiased, robust manner. Where there is a lack of data, HTA can be used to generate information. HTA is not only relevant to Europe: it has been used by healthcare providers across the world, and its use is increasing. HTA processes varies from country to country – even within countries.

Closely linked to HTA is reimbursement. Health insurers are not automatically allowed to provide cover for any new medicine that comes onto the market. Governments decide what drugs fall under the standard health insurance package.

About the L@SW Expert Classes

LS@W Expert Classes are a series of targeted workshops organized in close collaboration with industry experts on relevant topics for Life Sciences and Medical Technologies Startups. These small-scale Expert Classes are specially organized for alumni and participants of the Venture Challenge, Value Centre, MedtechPartners, BiotechPartner and Take off and are free of charge. Read more and check out the date(s) for the next edition >>


Send an email to Ellen de Waal:, adding the following details: First name – suffix -last name – email – phone and/or cell phone; Name of startup – status startup – stage of your startup; Questions for the experts. Note: Startups not (yet) part of our LS@W community but who are interested to join are welcome provided you match our community profile.

Thank you

We thank our 2017/2018 contributing Experts from: Loyens & Loeff, YesDelft, TU Delft/Delft Enterprises, NLO, European Patent and Trademark Attorneys, DSM Global Business Incubator, TU/E Innovation Lab, Usono, Philips, M Ventures, RVO, Merck Ventures, 2-BBB, Aglaia BioMedical Ventures, Netherlands Enterprise Agency (RVO), BioGeneration Ventures, Kite Pharma EU, Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Axon, eNovITe, Thuja Capital, Technology Transfer Office, Erasmus MC, European Patent Office, InnovationQuarter, Luris, BioPartner Leiden, PSR Orphan Experts, Paul Janssen Futurelab Leiden, Utrecht Holding, MDxHealth, Julius Center THINC, UMC Utrecht, Vereniging Innovatieve Geneesmiddelen,  UMotion, Sciences Affairs.